Year All 2026 September 8, 2026 Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million August 3, 2026 Korsana Biosciences Strengthens Leadership with Executive and Board Appointments to Support Next Phase of Growth April 1, 2026 Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement March 16, 2026 Korsana Biosciences Appoints Mark Vignola, Ph.D., as Chief Financial Officer March 12, 2026 Korsana Biosciences to Present at the Stifel 2026 Virtual CNS Forum February 18, 2026 Korsana Biosciences Emerges from Stealth with $175 Millon in Funding to Advance Potential Best-in-Class Therapeutics for Neurodegenerative Diseases
September 8, 2026 Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million
August 3, 2026 Korsana Biosciences Strengthens Leadership with Executive and Board Appointments to Support Next Phase of Growth
February 18, 2026 Korsana Biosciences Emerges from Stealth with $175 Millon in Funding to Advance Potential Best-in-Class Therapeutics for Neurodegenerative Diseases
